Last reviewed · How we verify
Botulinum Toxin Type A 900kD
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botulinum Toxin Type A 900kD |
|---|---|
| Also known as | BOTOX® |
| Sponsor | Allergan |
| Drug class | Neurotoxin; acetylcholine release inhibitor |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Biologic |
| Therapeutic area | Neurology; Aesthetics; Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25 (synaptosome-associated protein of 25 kDa), preventing acetylcholine vesicles from fusing with the presynaptic membrane. This results in flaccid paralysis of the injected muscle that typically lasts 3-4 months. The 900 kD formulation refers to the molecular weight of the toxin-protein complex, which includes associated proteins that may influence potency and duration.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Severe primary axillary hyperhidrosis
- Glabellar lines (cosmetic)
- Crow's feet (cosmetic)
- Forehead lines (cosmetic)
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Flu-like symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum Toxin Type A 900kD CI brief — competitive landscape report
- Botulinum Toxin Type A 900kD updates RSS · CI watch RSS
- Allergan portfolio CI